Stock APLT APPLIED THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Real-time Estimate Cboe BZX
Other stock markets
 14:50:56 2024-05-01 EDT 		5-day change 1st Jan Change
4.53 USD +2.49% Intraday chart for Applied Therapeutics, Inc. +3.48% +33.13%
04-15 Applied Therapeutics, Inc. Announces Management Changes CI
03-28 Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
GL
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
GL
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
GL
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
GL
Applied Therapeutics Announces $100 Million Private Placement
GL
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
GL
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
AQ
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
GL
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
AQ
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
GL
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat for Treatment of Classic Galactosemia
AQ
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
AQ
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
GL
Applied Therapeutics Reports Third Quarter 2023 Financial Results
GL
Applied Therapeutics Reports Third Quarter 2023 Financial Results
AQ
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
GL
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
GL
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
AQ
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
GL
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat for Treatment of Classic Galactosemia to FDA in Q4 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLT Stock
  4. News Applied Therapeutics, Inc.
  5. Press Releases